diet doctors

Telehealth Weight Loss Market Worth $6.9 Billion And Growing

April 13, 2024 Marketdata LLC (parent company of DietBusinessWatch) has just released new research, a report entitled: “The Telehealth Weight Loss Market”. The market for weight loss programs delivered via telehealth / telemedicine companies is worth $6.9 billion, and growing. Telehealth soared during the pandemic in 2020 as consumers stayed home and communicated with their […]

Telehealth Weight Loss Market Worth $6.9 Billion And Growing Read More »

Oprah’s TV Special Falls Short

News / John LaRosa

March 19, 2024 Last night Oprah Winfrey hosted a TV special investigating the popular GLP-1 diet drugs. The stories by people who lost significant weight were good, as was the information about obesity being a disease and not just a lack of willpower. However, in our opinion, some very important topics were not even mentioned.

Oprah’s TV Special Falls Short Read More »

Eli Lilly Offers Access To Zepbound via Amazon

News / John LaRosa

March 14, 2024 The U.S. pharmaceutical giant Eli Lilly is partnering with Amazon to help distribute its prescription drugs, notably its new weight loss treatment called Zepbound. Eli Lilly is using Amazon Pharmacy to distribute Zepbound to people’s homes through the drug maker’s new direct-to-consumer program. Going forward, Amazon Pharmacy will deliver drugs from Eli

Eli Lilly Offers Access To Zepbound via Amazon Read More »

U.S. Weight Loss Market Worth $90 Billion, Boosted by Diet Drugs

News / John LaRosa

March 4, 2024 U.S. Weight Loss Market Now Worth $90 Billion, Obesity Drug Sales Soar March 4, 2024 Marketdata LLC has just published a new analysis of the weight loss market: “The U.S. Weight Loss Market: 2024 Status Report & Forecast”, March 2024, 107 Pages Some findings: The total U.S. weight loss market is estimated

U.S. Weight Loss Market Worth $90 Billion, Boosted by Diet Drugs Read More »

Weight Watchers Reports Q4 and 2023 Results

News / John LaRosa

Feb. 28, 2024 WW reported its results for Q4 2023 and the full year today. WW reported results in line with analysts’ expectations in Q4 FY2023, with revenue down 8% year on year to $206 million. “2023 was a pivotal year as we began transforming our business for the future. We returned WeightWatchers to year

Weight Watchers Reports Q4 and 2023 Results Read More »

Medifast Reports Q4 and Full Year 2023 Results

News / John LaRosa

Feb. 20, 2024 Medifast reported full-year and Q4 results on February 20, 2023. 2023 revenues came in at $1.07 billion. The company employed 41,100 active earning Optavia health coaches, who had quarterly earnings of $4,648 (or $18,592 on an annual rate). Management said that: “We are realigning our business to respond to the evolving dynamics

Medifast Reports Q4 and Full Year 2023 Results Read More »

Eli Lilly Offers Weight Loss Drug Direct to Consumers

News / John LaRosa

January 5, 2023 Eli Lilly and Company launched a website, lillydirect.com, to enable people to directly order from the drug maker including its weight-loss medicine Zepbound as well as connect people with obesity and other conditions with telehealth companies. The service, called LillyDirect, comes on the back on extraordinary demand seen over the last year

Eli Lilly Offers Weight Loss Drug Direct to Consumers Read More »

Semaglutide Boom – The Beginning of a Decline? New FDA Report

News / John LaRosa

January 4, 2024 The history of weight loss drugs in the U.S. is filled with meds that were taken off the market due to nasty side effects, going back to the phen/fen crisis of 1997. Many more followed (Belviq, Qsymia, Taranabant, Acomplia) . These side effects did not emerge until years after entering the market

Semaglutide Boom – The Beginning of a Decline? New FDA Report Read More »

New Competitor – RO.co (Roman Health Ventures)

News / John LaRosa

Dec. 30, 2023 We have started to see TV commercials touting a company called RO, for weight loss. Apparently, this company entered the weight loss market in January 2023, providing GLP-1 weight loss drugs plus coaching, Ro is a direct-to-patient healthcare company with a mission of helping patients achieve their health goals by delivering the

New Competitor – RO.co (Roman Health Ventures) Read More »

More Obesity Drugs in the Pipeline – Boehringer Ingelheim

News / John LaRosa

August 20, 2023 Boehringer Ingelheim could soon stake a claim in the lucrative obesity treatment market after the pharma company said it has advanced a candidate into three Phase III trials following promising data. Servodutide, the company’s glucagon/glucagon-like peptide 1 (GLP-1) receptor dual agonist co-developed with Zeland Pharma, demonstrated up to 19% weight loss after

More Obesity Drugs in the Pipeline – Boehringer Ingelheim Read More »

(813) 971-8080